<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>4d Molecular Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc</link>
<description>Latest news and press releases for 4d Molecular Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 07 May 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/4d-molecular-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835693678dffbe2df0f1abf.webp</url>
<title>4d Molecular Therapeutics, Inc.</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc</link>
</image>
<item>
<title>4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-first-quarter-2026-financial-results-operational-highlights-and-expected-upcoming-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-first-quarter-2026-financial-results-operational-highlights-and-expected-upcoming-milestones</guid>
<pubDate>Thu, 07 May 2026 20:05:00 GMT</pubDate>
<description>4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 4FRONT-2 enrollment completion expected in H2 2026; topline data expected in H2 2027 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2 2026$458 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSW</description>
</item>
<item>
<title>4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-full-year-2025-financial-results-operational-highlights-and-expected-upcoming-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-full-year-2025-financial-results-operational-highlights-and-expected-upcoming-milestones</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from</description>
</item>
<item>
<title>4DMT to Participate in Upcoming Investor Meetings</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-to-participate-in-upcoming-investor-meetings</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-to-participate-in-upcoming-investor-meetings</guid>
<pubDate>Mon, 16 Mar 2026 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in March. Leerink Partners Mountain Meeting Event Date:March 22-25, 2026 R</description>
</item>
<item>
<title>4DMT Announces New Employment Inducement Grants</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-employment-inducement-grants-210500894</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-employment-inducement-grants-210500894</guid>
<pubDate>Fri, 13 Feb 2026 21:05:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company’s board of directors granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs). The RS</description>
</item>
<item>
<title>4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-completes-enrollment-4front-1-130000794</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-completes-enrollment-4front-1-130000794</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong interest from investigators and patients Topline data from 4FRONT-1 expected in H1 20274FRONT-2 global site activation momentum continues, with enrollment completion on track for H2 2026 and topline data expected in H2 2027 EMERYVILLE, Calif., Feb.</description>
</item>
<item>
<title>4DMT Provides Company Update and Anticipated Development Milestones for 2026</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-provides-company-anticipated-development-130000053</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-provides-company-anticipated-development-130000053</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Phase 2b data expected mid-20264D-150 DME global Phase 3 trial initiation expected Q3 2026; 2-year SPECTRA Phase 1/2 data expected H2 2026Appointed Glenn Sblendorio to Board of Directors, adding deep commercial and operating experience, including in ret</description>
</item>
<item>
<title>4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-positive-interim-clinical-120000944</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-positive-interim-clinical-120000944</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data support 4D-710’s potential to be a durable, redosable, variant-agnostic, disease-modifying treatment for people with cystic fibrosis lung disease with high unmet needWebcast today at 8:00 a.m. ET with distinguished cystic fibrosis KOLs EMERYVILLE, Calif.</description>
</item>
<item>
<title>4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-present-44th-annual-j-130000814</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-present-44th-annual-j-130000814</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference. Members of the management team will also be available for one-on-one meetings. 44th Annual J</description>
</item>
<item>
<title>4DMT to Participate in 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-8th-annual-evercore-130000506</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-8th-annual-evercore-130000506</guid>
<pubDate>Thu, 20 Nov 2025 13:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference. Members of the management team will also be available for one-on-one meeti</description>
</item>
<item>
<title>4DMT Appoints Kristian Humer as Chief Financial Officer</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-appoints-kristian-humer-chief-110000951</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-appoints-kristian-humer-chief-110000951</guid>
<pubDate>Mon, 17 Nov 2025 11:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company’s financial strategy and operations, including responsibility for financial planni</description>
</item>
<item>
<title>4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-third-quarter-2025-130000805</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-third-quarter-2025-130000805</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to receive $85 million in upfront cash and expects to receive at least $50 million from cost sharing Announced positive long-term safety and efficacy data with 1.5 to 2 years of follow-up from the Phase 1/2 PRISM clinical trial in wet AMD Completed equity offering providing net proceeds of ~$93 million Announced up to $11 million equity investment from the Cy</description>
</item>
<item>
<title>4DMT to Participate in Jefferies 2025 London Healthcare Conference</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-jefferies-2025-london-210500585</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-jefferies-2025-london-210500585</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference. Members of the management team will also be available for one-on-one mee</description>
</item>
<item>
<title>4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-pricing-100-million-112300865</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-pricing-100-million-112300865</guid>
<pubDate>Thu, 06 Nov 2025 11:23:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the pricing of an underwritten offering of 8,385,809 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 sha</description>
</item>
<item>
<title>4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-positive-long-term-110000572</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-positive-long-term-110000572</guid>
<pubDate>Thu, 06 Nov 2025 11:00:00 GMT</pubDate>
<description>4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-upStrong dose response in favor of Phase 3 dose (3E10 vg/eye) continues to be demonstrated4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings, consistent with previous updates, with up to 3.5 years of follow-up4FRONT-1</description>
</item>
<item>
<title>4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-exclusive-license-agreement-030200625</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-exclusive-license-agreement-030200625</guid>
<pubDate>Fri, 31 Oct 2025 03:02:00 GMT</pubDate>
<description>4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336 million in potential regulatory and commercial milestones and tiered double-digit royalties depending on net sales in Otsuka’s territoriesProceeds and cost sharing expected to support global Phase 3 clinical trial in DME and pre-commercial activities EMERYVILLE, Calif., Oct. 30, 2025</description>
</item>
<item>
<title>4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-chardans-9th-annual-120000212</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-chardans-9th-annual-120000212</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in panel discussions at Chardan’s 9th Annual Genetic Medicines Conference on October 21st, 2025. Members of the management team will also be av</description>
</item>
<item>
<title>4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-advances-4d-710-phase-120000295</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-advances-4d-710-phase-120000295</guid>
<pubDate>Mon, 13 Oct 2025 12:00:00 GMT</pubDate>
<description>Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis, following program and clinical data review by its independent scientific advisors Funding supports second 4D-710 dosing ≥1 year post initial Phase 1 dose, advancement into Phase 2, and Phase 3 readinessEnrollment in the Phase 2 stage of the AEROW clinical trial is currently underway, with 2.5E14 vg selected as the anticipated pivotal and commercial dose EMERYVILL</description>
</item>
<item>
<title>4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-leadership-expansion-proven-120000769</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-announces-leadership-expansion-proven-120000769</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of distinguished retina industry advisors enhances global development and commercialization expertise EMERYVILLE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology</description>
</item>
<item>
<title>4DMT to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-upcoming-investor-conferences-120000763</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-participate-upcoming-investor-conferences-120000763</guid>
<pubDate>Mon, 25 Aug 2025 12:00:00 GMT</pubDate>
<description>EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in September. Members of the management team will also be available for one-on-one meetings.</description>
</item>
<item>
<title>4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones</title>
<link>https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-second-quarter-2025-120000044</link>
<guid isPermaLink="true">https://6ix.com/company/4d-molecular-therapeutics-inc/news/4dmt-reports-second-quarter-2025-120000044</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week results from 4D-150 SPECTRA clinical trial in DME Streamlined organization to drive late-stage execution$417 million in cash, cash equivalents and marketable securities as of June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular</description>
</item>
</channel>
</rss>